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1. INTRODUCTION 
1.1 Receptor tyrosine kinases 
Receptor tyrosine kinases (RTKs) are membrane proteins that are involved in important 
cellular processes, such as proliferation, differentiation, cell migration, cell survival, metabolism 
and cell cycle control. The human genome harbors 58 known members of the RTK family, which 
are divided into 20 subfamilies (Figure 1). They all share similar molecular structures and 
mechanisms of action. They contain a ligand binding region, located in the extracellular domain, 
a single transmembrane helix, and a cytoplasmic region with the tyrosine kinase domain plus 
carboxy (C-) terminal and juxtamembrane regulatory regions (Lemmon and Schlessinger, 2010).  
Upon ligand binding, self-association of the extracellular domains leads to dimerization of two 
receptor molecules. This is followed by activation of the tyrosine kinase domains and intracellular 
autophosphorylation events. In most cases, phosphorylated tyrosine residues are located in the C-
terminal tail of the receptor, the juxtamembrane region or the kinase insert region, which are 
readily accessible to downstream signalling proteins. The resulting phosphotyrosines function as 
specific sites for the assembly of downstream signalling molecules that are recruited to the receptor 
(Hubbard and Miller, 2007; Lemmon and Schlessinger, 2010; Regad, 2015). These proteins can 
be enzymes, regulatory molecules, or adaptors that typically bind through Src homology-2 (SH2) 
or phosphotyrosine-binding (PTB) domains and will activate downstream signalling cascades 
(Schlessinger and Lemmon, 2003; Yao et al., 2017). 
Numerous human diseases result from genetic changes or abnormalities that alter RTK 
activity, abundance, cellular distribution or regulation. Constitutively active RTKs cause 
activation of intracellular signalling pathways that can result in increased cell proliferation, 
survival, invasion, metastasis and overall aberrant cell function.  Mutated RTKs have been 
connected to cancers, diabetes, inflammation, severe bone disorders, arteriosclerosis and 
angiogenesis. Aberrant RTK activation in human cancers is mediated by four principal 
mechanisms: autocrine activation, chromosomal translocations, RTK overexpression, or gain-of-
function mutations (Regad, 2015). Understanding the molecular mechanisms of RTK signalling 
and regulation is critical to establish pathophysiological features of many diseases and to develop 
new generations of drugs targeting RTKs or components of their signalling pathways (Yao et al., 
2017).  
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Figure 1. The schematic architecture of receptor tyrosine kinase families. Human receptor 
tyrosine kinases (RTKs) contain 20 subfamilies with 58 RTKs listed beneath each receptor family 
(adapted from Lemmon and Schlessinger, 2010).  
 
1.2 The ErbB family of receptor tyrosine kinases 
The human epidermal growth factor receptor (ErbB or EGFR) family belongs to large group 
of receptor tyrosine kinases (RTKs) that control many cellular processes as response to 
extracellular stimuli.  The ErbB family consists of four members: ErbB1 (EGFR, HER1), ErbB2 
(HER2, neu in rodents), ErbB3 (HER3) and ErbB4 (HER4). This family of receptors is expressed 
in epithelial, mesenchymal and neuronal cells and their cellular progenitors. Mice deficient in ErbB 
family members display a wide range of phenotypes connected with cell differentiation, 
proliferation, migration and survival, and null mutation of ErbB genes results in embryonic or 
perinatal lethality. Multiple signal transduction pathways are activated by ErbB family members, 
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such as the phosphatidylinositol 3-kinase (PI3K)/Akt (PKB) pathway that plays an important role 
in mediating cell survival, the Ras/Raf/MEK/ERK1/2 and phospholipase C (PLCγ) pathways that 
participate in cell proliferation, the STAT pathway that has an important role in maintaining 
epithelial cell polarity and adhesion, and the Par6-atypical PKC pathway important in epithelial 
organisation. In addition to important signalling roles from the cell membrane, there is also 
evidence that these receptors are translocated to the nucleus where they influence gene 
transcription. The ErbB proteins up-regulate many genes including cyclin D1, b-myb, 
cyclooxygenase-2, and the genes of iNOS/NO pathway (Wieduwilt and Moasser, 2008; Roskoski, 
2014).   
The ErbB family members are structurally related single chain transmembrane glycoproteins 
consisting of an extracellular ectodomain, a transmembrane domain, a short juxtamembrane 
section, a tyrosine kinase domain and a tyrosine-containing C-terminal tail (Figure 2). The general 
mechanism for activation of the ErbB family is the same as for all RTKs: ligands bind to 
extracellular domain of two receptors and induce formation of the activated state, whereby the 
cytoplasmic kinase domains phosphorylate tyrosine residues and creating docking sites for diverse 
proteins included in downstream signalling. Seven ligands bind to ErbB1, two bind to ErbB3 and 
seven bind to ErbB4. ErbB2 lacks its own ligand. All the ligands are expressed as cell membrane-
anchored proteins that are proteolytically processed to realise soluble molecules. They act over 
short distances from their sites of generation and may act in an autocrine, juxtacrine or paracrine 
fashion.  An extracellular ligand-binding domain is divided into four parts: domains I and II, which 
are leucine-rich repeats that participate in ligand binding, and domains III and IV, which have 
numerous cysteine residues that participle in disulfide bond formation. Ligand binding to the 
ectodomain of the receptor promotes homo- and heterodimer formation between two receptor 
molecules, which is crucial for activation of the intracellular tyrosine kinase domain and 
phosphorylation of the C-terminal tail. Crystal structures of receptors show a “tethered” inactive 
conformation, in which the beta-hairpin or dimerization loop of domain II interacts with the 
tethering arm of domain IV. The bivalent ligand binding promotes a conformational change where 
dimerization loop of one receptor molecule interacts with dimerization loop of second receptor 
molecule leading to an extended form (Wieduwilt and Moasser, 2008; Lemmon and Schlessinger, 
2010; Roskoski, 2014; Purba, Saita and Maruyama, 2017). ErbB1 and ErbB4 can be considered 
as fully functional receptors with the ability to both bind ligands and autophosphorylate C-terminal 
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tails through functional intracellular tyrosine kinase activity. ErbB2 does not bind to any growth 
factor, but it exists in an extended and open conformation, in which the dimerization loop is 
exposed. Unbound  ErbB2 is available for dimerization with other ErbB family members and it is 
the favored dimerization partner (Wieduwilt and Moasser, 2008; Roskoski, 2014), although active 
ErbB1 and ErbB4 homodimers can form. ErbB2 homodimers are unlikely, but induced 
overexpression leads to formation of a functional homodimer. ErbB1/2/4 possess protein kinase 
activity, while ErbB3 is kinase impaired. ErbB1/2/4 share conserved catalytically important 
residues within the kinase domain. ErbB3 homodimers fail to stimulate protein kinase activity and 
downstream signalling, and pseudokinase ErbB3 possesses just 0.1% of the autophosphorylation 
activity of ErbB1 (Roskoski, 2014). 
 
Figure 2. The schematic structure of ErbB receptors. The extracellular domain is structurally 
divided into domains I and III that directly interact with ligand (except for ErbB2) and domains II 
and IV which form dimers. Short transmembrane and juxtamembrane domains link the 
extracellular domain to the tyrosine kinase domain and the C-terminal tail. The kinase domain of 
ErbB3 is kinase-impaired. The extracellular domain of ErbB2 does not bind ligands. 
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1.2.1 ErbB family in cancer 
Several malignancies are associated with aberrant signalling through the ErbB family of 
receptors. Overexpression and mutation of ErbB family members have been implicated in different 
type of cancers including lung, breast, stomach, colon, ovary, prostate, kidney, head, pancreatic 
and brain cancers. Early evidence for the role of ErbB receptors as protooncogenes came from 
identification of the rodent homolog neu oncogene that induces neuroblastomas in rats (Wieduwilt 
and Moasser, 2008; Lemmon and Schlessinger, 2010). Principle mechanisms of oncogenic 
activation of ErbB receptors have been identified; amplification and overexpression, molecular 
alterations and inhibition of phosphatase activity (Herter-Sprie, Greulich and Wong, 2013), 
leading to aberrant activation of downstream pathways, thereby promoting cell proliferation, 
survival, invasion and metastasis. Lung cancer is the most common type of cancer in the wold, and 
85% cases are non-small cell lung cancer (NSCLC). ErbB1 has an important role in the 
pathogenesis of NSCLC where it is amplified in 5-10%, overexpressed in 5-20% and mutated in 
10-40% of cases (Wieduwilt and Moasser, 2008; Roskoski, 2014; Regad, 2015). Gene 
amplification of ErbB2 and receptor overexpression have been reported in 20-30% of breast 
cancers. Breast cancer is the leading cause of female cancer deaths globally and ErbB2 
amplification is associated with decreased survival and shorter relapse time (Moasser, 2007; 
Wieduwilt and Moasser, 2008; Lemmon and Schlessinger, 2010; Roskoski, 2014; Regad, 2015).  
Molecular target therapeutics have been developed and approved by the US Food and Drug 
Administration (FDA) for threating aberrant ErbB receptors in cancers and other diseases. These 
drugs are divided into two categories: small molecule inhibitors that target the intracellular tyrosine 
kinase domain and monoclonal antibodies that target the extracellular domain. Development of 
drug resistance is a common event in many cases, for example a new activating mutation 
overcoming the drug-mediated inhibition of receptors (Lemmon and Schlessinger, 2010). 
Substitution T798M in the kinase domain of ErbB2 is a gatekeeper mutation allowing continued 
proliferation of breast cancer cells in the presence of the small molecule inhibitor Lapatinib or the 
monoclonal antibody Trastuzumab (Herter-Sprie, Greulich and Wong, 2013; Rexer et al., 2013). 
Another interesting oncogenic form of ErbB2 protein is an alternative splice form containing an 
in-frame deletion of 48 bp of exon 16 in the extracellular domain. This deletion occurs in the same 
region that is muted in the neu oncogene in mice. ErbB2 ex16del appears to be a more aggressive 
variant compared to wt ErbB2 and this transcript represents about 9% of ErbB2 transcripts in breast 
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carcinomas. This deletion in the extracellular domain leads to an altered conformation that 
promotes intermolecular disulfide bonding and active ErbB2 homodimers. ErbB2 ex16del has also 
been implicated in resistance of HER2 positive tumors to anti-ErbB2 therapies (Castiglioni et al., 
2006; Moasser, 2007; Jackson et al., 2013).  
1.3 Src homology 2 and phosphotyrosine-binding domains 
Upon the activation of RTKs, the autophosphorylated tyrosine residues become platforms for 
the recruitment of different signalling proteins. The specific interactions of effector proteins that 
contain phosphotyrosine binding motifs activate signalling pathways, such as the Ras-mitogen 
activated protein kinase (MAPK), phosphoinositide-3- kinase (PI3K)- Akt, and phospholipase C-
γ (PLC-γ) pathways involved in different cell processes (Wagner et al., 2013). Src homology 
region 2 (SH2) and phosphotyrosine-binding (PTB) domains are identified as small protein 
modules of 50 to 200 amino acids that recognize phosphorylated tyrosine (pTyr) in RTKs and 
other signalling proteins. They are found in a diverse set of proteins and provide specific 
stimulation of downstream pathways. SH2 domain-containing proteins bind to their target 
according to the specific phosphorylated tyrosine, and most PTB domains proteins bind 
constitutively (Schlessinger and Lemmon, 2003). 
SH2 domains were first defined as conserved sequences that regulate the tyrosine kinase 
activity of v-FPS and members of the Src kinase family, and they have important roles in mediating 
cell signalling by RTKs and non-receptor protein tyrosine kinases (Schlessinger and Lemmon, 
2003). For some SH2 domains, crystal structures have been solved and typically they consist of 
three or four β-strands and two α-helices. A positively charged binding pocket on the surface has 
a highly conserved FLVR motif with a critical arginine residue that binds the pTyr of target 
ligands. The affinity of an SH2 domain for pTyr depends on the amino acid sequence surrounding 
the pTyr residue (Wagner et al., 2013). Proteins that contain SH2 domains belong to different 
protein families according to their function, including enzymes (e.g. kinases, phosphatases, 
guanine nucleotide exchange factors, GTPase activating proteins), adaptors, scaffold proteins, 
signal regulators and transcription factors (Schlessinger and Lemmon, 2003).  
PTB domains appear to share the same folding pattern, termed the pleckstrin homology (PH) 
domain “superfold”. They are composed of two β-strands capped by α-helix that together make up 
a highly conserved ligand-binding pocket. The NPXY motif is commonly present among PTB 
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domain substrates and is considered the canonical binding motif. pTyr binding is not required for 
all PTB domains, and in fact the binding of most PTB domains is independent of pTyr.  Because 
PTB domains are more diverse in sequence than SH2 domains, they have more diverse functions 
(Schlessinger and Lemmon, 2003; Wagner et al., 2013).  
1.4  Methods for analysing protein-protein interaction 
Cells are the basic unit of life, composed of multiple diverse biomolecular systems. Proteins 
are components of these systems with many different and important functions such as molecular 
machines, sensors, transporters and structural elements (Snider et al., 2015). Many biological 
processes are sustained by protein-protein interactions and identifying these interactions is very 
important for understanding cellular function and mechanisms, and for developing therapies and 
drugs for treatment of human diseases. To date, only around 10% of protein-protein interactions 
(PPIs) in human cells are known (Kotlyar et al., 2015). For characterization of PPIs and to map 
interactomes, many methods have been developed. Biochemical, genetic and cell biological 
approaches have been used for identification of a large number of PPIs, and while numerous 
methods are available, each of them has advantages and limitations. It is important to select a 
suitable method for studying interacting partners of the protein of interest, and to validate detected 
PPIs with another technique.   
The classic genetic approach first developed was yeast two-hybrid (Y2H), which is still one of 
the most popular PPI identification methods. It is a protein complementation assay based on the 
physical separation of two functional domains of transcription factors that are fused to candidate 
interacting proteins. Upon interaction, both domains work together as a functional transcription 
factor leading to expression of a reporter gene. Y2H is used for detection of binary interactions in 
both large scale screening studies and smaller efforts investigating specific PPIs, but it is not 
suitable for probing interactions of membrane proteins (Fields and Song, 1989; Snider et al., 2015). 
Hence, the membrane yeast two-hybrid (MYTH) assay was designed for analysis of the 
interactions of membrane proteins. It is based on split ubiquitin approach, where the ubiquitin 
protein is divided into two fragments, each fused to one of the proteins of interest. The C-terminal 
ubiquitin moiety is also fused to an artificial transcription factor. Interaction of bait and prey 
protein brings the ubiquitin moieties into close proximity, and allows deubiquitinating enzymes to 
cleave and release the artificial transcription factor, which activates a reporter system (Stagljar et 
al., 1998). For both Y2H and MYTH, the biggest disadvantages are problems associated with the 
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expression, modification and interaction of non-native proteins in the yeast host (Snider et al., 
2015).  
A widely used biochemical method for detecting PPIs is co-immunoprecipitaion (Co-IP). Cell 
lysates are generated and the protein complex is precipitated using the antibody against the protein 
of interest fixed to a solid support. Bound proteins are eluted and analysed (Phizicky and Fields, 
1995). Disadvantages include that proteins are not in a native cell environment, and it is hard to 
isolate membrane proteins. The luminescence-based mammalian interactome mapping (LUMIER) 
assay is a high-throughput technology based on Co-IP. LUMIER was developed for detecting 
pathway-specific, posttranslational modification dependent PPIs, constitutive protein interactions 
and interactions involving transmembrane receptors in mammalian cells. In this method, Renilla 
luciferase enzyme is fused to proteins of interest, which are then coexpressed with individual 
FLAG-tagged partners in the desired cell line (Barrios-Rodiles et al., 2005). A major disadvantage 
of the LUMIER method because is based on Co-IP is that it requires cell lysis that can disrupt 
weak and transient PPIs and introduce potential artefacts (Snider et al., 2015).   
An important feature of PPIs is also the subcellular localization of protein complexes in living 
cells. New technologies have been developed for visualizing the interactions, including non-
invasive methods using bioluminescence or fluorescence resonance energy transfer (BRET or 
FRET) and those centered on protein fragment complementation, such as bimolecular fluorescence 
complementation (BiFC). The basic principle of RET is transfer of energy from an excited donor 
to a nearby acceptor molecule. Donors molecules are fluorophores in FRET, whereas in BRET the 
donor is an enzyme that catalyse a bioluminescent substrate. Bait and prey proteins are fused on 
donor and acceptor molecules and if two proteins interact, energy transfer occurs, producing a 
signal. BiFC technique is based on generation of a fluorescent signal from two non-fluorescent 
fragments of fluorescent protein. The two halves are genetically fused to the proteins under study 
and upon interaction a fluorescent signal is detectable (Ciruela, 2008).  
A popular technology for high-throughput protein interaction mapping is affinity purification-
mass spectrometry (AP-MS).  Affinity purification refers to capture of biological material via 
specific enrichment with ligand coupled to a solid support. For detection of PPIs, cells expressing 
a protein of interest are cultured and harvested allowing purification of the protein by an affinity 
reagent targeting the protein itself or an epitope tag. Once affinity-purified, captured proteins are 
digested with protease, resulting peptides are separated by liquid chromatography and identified 
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by mass spectrometry. AP-MS is a library-independent method and it can be used to analyse the 
same baits across multiple tissue or cell lines, especially important for studying differences in the 
interactomes of normal and disease states (Dunham et al., 2012).  
Bioinformatics-based approaches are also used for computational PPI prediction. These tools 
help identify candidate proteins for high-throughput screens prior to experimental work, which 
may reduce the cost of interactome mapping. For example, FpClass is an in silico method to predict 
high-confidence PPIs proteome-wide. The disadvantage is that the estimated false positive rate is 
60% (Kotlyar et al., 2015).  
The recently developed Mammalian Membrane Two-Hybrid (MaMTH) assay is a protein-
complementation technique for detecting membrane protein interactions in mammalian cells. In 
comparison to the methods above, MaMTH is suitable for detecting transient and modification-
dependent PPIs in response to different cellular conditions (Petschnigg et al., 2014). This method 
was used for the following work.  
1.4.1 The Mammalian Membrane Two-hybrid Assay 
The Mammalian Membrane Two-Hybrid (MaMTH) assay was first published by Julia 
Petschnigg et al. in Nature Methods and developed in Igor Stagljar’s group as a split ubiquitin 
two-hybrid approach to study PPIs of full-length integral membrane or membrane-associated 
proteins in mammalian cells (Petschnigg et al., 2014; Saraon et al., 2017).  
MaMTH is based on previously described split ubiquitin approaches (Johnsson and 
Varshavsky, 1994) and is derived from the membrane yeast two-hybrid (MYTH) assay (Stagljar 
et al., 1998). A membrane bait protein of interest is tagged with C-terminal moiety of ubiquitin 
(Cub) followed by a chimeric transcription factor (TF), and cytosolic or membrane-bound prey 
proteins have the N-terminal unit of ubiquitin (Nub) bound. The proteins can be C- or N-tagged 
depending on the orientation and nature of the protein, and this has to be decided based on previous 
work or experimentally. The principle behind MaMTH is described in Figure 3. Upon bait and 
prey interaction, pseudo-ubiquitin is formed by the association of Nub and Cub. Deubiquitinating 
enzymes (DUBs) are recruited, leading to a proteolytic cleavage whereby the TF gets released. 
The reporter signal is activated by the TF which enters the nucleus and binds the Upstream 
Activating Sequence (UAS) or operator. Different TFs can be used depending on the reporter 
system, for example lexA or GAL4-based. Current MaMTH assays are all carried out in HEK 293 
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cells stably expressing a reporter construct either containing eight lexA operator repeats or five 
GAL4 UAS repeats, followed by the reporter gene (Petschnigg et al., 2014; Saraon et al., 2017). 
In the work described in this thesis, the transcription factor used was comprised of amino acids 1-
147 of the GAL4 protein (DNA binding domain) fused to amino acids 364-550 of mouse NF-κΒ.  
To express prey and bait in the MaMTH reporter cells there are four possible options. First is 
transient transfection with both bait and prey. The second variation is stable expression of the bait 
in the cell line followed by transient transfection of the prey DNA. The third option is to have a 
stably expressed prey and transiently expressed bait. The last option is stably expressed both bait 
and prey. 
The cells being transfected contain stable integrated region for binding the TF. The output can 
be green fluorescent protein (GFP) or luciferase, which may be secreted Gaussia luciferase or 
intracellular Firefly luciferase. HEK 293 cells designated B0166 were used in the work described 
in this thesis, which have stably integrated GAL4 UAS repeats followed by Gaussia luciferase 
gene, and are engineered to stably express bait proteins of interest. 
The expression of transiently-expressed prey protein can vary between different transfections. 
To minimize this influence, the prey construct contains red fluorescent protein (mCherry), which 
is separated from the prey coding region by a P2A sequence, and which gets translated at a level 
correlating with the expression of the protein of interest. The RFP levels can therefore be an 
indication of transfection efficiency.   
An important advantage of MaMTH is that full length membrane protein interactions can be 
analysed directly in their natural cellular membrane context. Additional advantages are low cost, 
high scalability and ready transferability to virtually any cell line of interest. The assay is highly 
sensitive, making it suitable for both the measurement of weak/transient interactions and for 
monitoring dynamic, “condition-dependent” PPIs. Limitations of the assay include the 
requirement for the bait to be associated with the membrane or other intracellular structures, to 
prevent non-specific activation of reporter system. Also, the termini of the membranes proteins 
fused to Cub or Nub must be cytosolic, in order to provide access to the DUBs (Snider et al., 2015; 
Saraon et al., 2017). The method is best suited for the detection of binary PPIs. The MaMTH assay 
is a powerful tool for mapping the interaction networks of membrane proteins and characterizing 
how these interactions respond to different cellular conditions. MaMTH detects interaction 
changes in response to ligands, starvation conditions, different post translational modifications, 
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etc. Therefore, the method is suitable for monitoring phosphorylation-dependent interaction, drug-
inhibited interactions or interaction patterns of wild type and mutant proteins (Petschnigg et al., 
2014; Petschnigg et al., 2017). Mammalian cell-based assays that can identify changes in PPIs 
conferred by aberrant signalling pathways can help understand disease mechanisms and define 
new drug targets. The MaMTH assay has been recently modified as a high-throughput, small 
molecule screening platform. This approach offers a significant advantage, allowing for rapid 
identification of low toxicity, physiologically active compounds directly in the natural context of 
the living mammalian cell (Snider and Saraon et al., manuscript under review).  
 
Figure 3. Schematic representation of the MaMTH system. Bait and prey proteins of interest 
are expressed in MaMTH reporter cells. A membrane bait protein is tagged with the C-terminal 
half of ubiquitin (Cub) followed by a chimeric transcription factor (TF) and cytosolic or 
membrane-bound prey protein has the N-terminal unit of ubiquitin (Nub) bound. The ubiquitin 
fragments remain inactive unless fused to two interacting proteins, whose proximity upon 
association drives reconstitution of the Cub and Nub into an active pseudo-ubiquitin molecule. 
This newly reconstituted ubiquitin is then target by human ubiquitin-specific proteases (DUBs) 
which cleave at the C-terminus of the Cub, releasing an artificial transcription factor (TF), which 
can then enter the nucleus and activate reporter gene transcription.  
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2. AIM OF THIS WORK 
The aim of this study was to map and characterise interactions between the ErbB2 receptor 
tyrosine kinase and proteins which contain SH2 and/or PTB domains using the MaMTH assay.  
First, using site directed mutagenesis and Gateway cloning, mutant versions of ErbB2 receptor 
(ex16del, T798M and K753A) were generated, and these were used to create MaMTH reporter 
cell lines stably expressing bait proteins of interest. The tetracycline concentration required to 
induce expression of the wild type and three mutant baits had to be optimized and the activation 
level determined through Western blot. All cell lines had to be tested with MaMTH using known 
positive and negative interactors to validate the system. The interactome was built by a biased 
screen of a 98 SH2/PTB protein-containing library against ErbB2 wild type. Some interactions 
were further tested to characterize if the SH2 domain of different interacting proteins mediated the 
interaction. Interactors were tested using oncogenic mutants ErbB2 ex16del and ErbB2 T798M 
with constitutive activation, and phosphorylation dependent interactions had to be characterised 
using inactive mutant ErbB2 K753A. 
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3.  MATERIALS AND METHODS 
3.1  Materials 
3.1.1 Chemicals and reagents 
Table 1. List of chemical and company.  
Chemical / reagent Company 
10 x TE (Tris HCl, EDTA) Buffer Tekanova 
20% sodium dodecyl sulfate (SDS) solution BioShop 
30% Acrylamide/Bis solution BioRad 
6 x DNA loading dye (LD) Thermo Fisher Scientific 
Acetic acid BioShop 
Agar BioShop 
Agarose Invitrogen 
Albumin BioShop 
Amersham ECL Selected Western Blotting 
Detection Reagent 
GE Healthcare 
Ammonium peroxydisulfate (APS) Thermo Fisher Scientific 
Calcium chloride (CaCl2)  BioShop 
Coelenterazine NanoLight Technology 
Complete tablets, protein inhibitor cocktail 
tablets 
Roche 
Coulter Isoton III Diluent Beckman Coulter 
Dimethyl Sulfoxide (DMSO) Fisher Bioreagents 
Dithiothreitol (DTT) BioShop 
Dpn1 (#R0176S) enzyme NEB 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
Dulbecco’s Phosphate Buffered Saline (PBS) Sigma Aldrich 
Eagles Minimum Essential Media (Opti MEM) Gibco 
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Ethanol Commercial Alcohols 
Ethylene glycol- bis (β-aminoethyl ether) -
N,N,N',N'- tetraacetic acid (EGTA) 
BioShop 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Fetal Bovine Serum (FBS) Gibco  
Gateway BP Clonase II enzyme mix Invitrogen 
Gateway LR Clonase II enzyme mix Invitrogen 
Glycerol BioShop 
Glycine BioShop 
Isopropyl alcohol Colenda 
KAPA Hifi PCR Kit KAPA Biosystems 
Lennox Broth (LB) BioShop 
N, N-bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES)  
Sigma Aldrich 
PageRuler Plus Prestained Protein Ladder Thermo Fisher Scientific 
Ponceau S  Sigma Aldrich 
Proteinase K Invitrogen 
Sodium chloride (NaCl) BioShop 
Sodium orthovanadate Santa Cruz Biotechonolgy 
Super Signal West PICO PLUS 
Chemiluminescent substrate 
Thermo Fisher Scientific  
Sybr Safe DNA Gel Stain Invitrogen 
Tetramethylethylenediamine (TEMED) Invitrogen 
Tris BioShop 
TritonX 100 Sigma Aldrich 
TrypLE Express  Gibco  
Tween 20 Bioshop 
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Versene  Gibco  
X-tremegene 9 DNA transfection reagents Roche 
β-glycerophosphate disodium salt hydrate Sigma Aldrich 
 
3.1.2 Antibiotics 
Table 2. List of antibiotics, working concentration and company. 
Antibiotics Working Concentration Company 
Blasticidin 15 µg/ml BioShop 
Carbenicillin 100 µg/ml BioShop 
Hygromycin B solution 100 mg/ml Sigma Aldrich 
Penicillin /Streptomycin  (10000 U/ml) / (10000 µg/ml) Gibco 
Spectinomycin 50 µg/ml BioShop 
Tetracycline  1 mg/ml BioShop 
 
3.1.3 Molecular biological kits 
Table 3. Molecular biological kits and company. 
Kit Company 
GenepHlow Gel/PCR Kit Geneaid 
Pierce BCA Proteins Assay kit Thermo Fisher Scientific 
Presto Mini Plasmid Kit Geneaid 
 
3.1.4 Antibodies 
Table 4. List of antibodies and company. 
Antibody Company 
FLAG Sigma Aldrich (#087K6002) 
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Goat anti-mouse BioRad (#1721011) 
Goat anti-rabbit BioRad (#1721019) 
HER2/ErbB2 Cell Signaling Technology (#2165) 
P44/42 MAPK (Erk1/2) Cell Signaling Technology (#9102S) 
Phospho-HER2/ErbB2 (Tyr1221/1222) Cell Signaling Technology (#2243S) 
Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) 
Cell Signaling Technology (#9101S) 
pY99 Santa Cruz Biotechnology 
(#NC9466639) 
V5- tag  Cell Signaling Technology (#13202S) 
α -  tubulin Santa Cruz Biotechnology (#L1416) 
 
3.1.5 Buffers and solutions 
Table 5. Buffers/solution and composition. 
Designation Composition 
BES (2x)  
 
50 nM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 6.96 
Cell culture medium 10 % FBS (v/v) 
1 % Penicillin/ streptomycin (v/v) 
DMEM 
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Cell lysis buffer H 50 mM, pH 7.3 β- glycerophosphate  
1.5 mM EGTA 
1 mM EDTA 
1 mM DTT 
0.1 mM orthovandate 
1 % TritonX 100 
LB agar medium (1L) 20 g LB 
20 g agar 
LB medium (1L) 20 g LB 
Running buffer (10x) 250 mM Tris  
960 mM glycine 
1 % SDS 
Sample buffer (4x) 40 % glycerol 
0.2 M Tris/HCl pH 6.8 
bromphenol blue 
8 % SDS 
0.1 M DTT 
TBST buffer (1x)  
 
20 mM Tris 
150 mM NaCl 
0.1% Tween20 
pH 7.6 
Transfer buffer (10x) 150 mM Tris base 
1.2 M glycine 
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3.1.6 Laboratory equipment 
Table 6. List of laboratory equipment, specification and manufacturer. 
Designation Specification Manufacturer 
Bacteria Incubator  VWR 
Bacteria Incubator Shaker Minitron Infors HT 
Biological Safety Cabinet CLASS II Type A2 Microzone Corporation 
Cell Counter Coulter Z series Beckman Coulter 
Cell Culture incubator Hera cell 150i Thermo Fisher Scientific 
Centrifuge 54150 Eppendorf  
Centrifuge Microfuge 18 Beckman Coulter 
Centrifuge 5810R Eppendorf  
DNA gel electrophoresis apparatus Mini-Sub Cell GT Cell BioRad 
Dry Baths AccuBlock Labnet International 
Luminometer Luminoskan Ascent Thermo Labsystems 
Microplate Reader Synergy Neo BioTek 
Microscope  Vista Vision VWR 
Protein gel electrophoresis 
apparatus 
Mini-PROTEAN Tetra 
Cell 
BioRad 
Spectrophotometer NanoDrop ND 1000 Thermo Fisher Scientific 
Thermal cycler Mastercycler epgradient Eppendorf 
Water Bath  VWR 
Western blotting apparatus  Criterion™ blotter BioRad 
X-ray developer SRX-101A Konica Minolta 
X-ray film for immunoblot 
detection  
 Mandel Scientific 
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3.1.7 Cell lines and bacteria strains 
Table 7. Bacteria strains. 
Bacteria strains Prepared 
Chemically – competent E. coli DH5α Inoue-Method  (Sambrook and Green, 2012) 
 
Table 8. List of cell lines and source. 
Cell lines Source 
HEK 293 B0166 (MaMTH reporter cell line) Made by Dr. Jamie Snider, Stagljar lab 
HEK 293 B0166 stable expression of ErbB2 Made by Luka Drecun, Stagljar lab 
HEK 293 B0166 stable expression of ErbB2 
ex16del 
Made during this work 
HEK 293 B0166 stable expression of ErbB2 
T798M 
Made during this work 
HEK 293 B0166 stable expression of ErbB2 
K753A 
Made during this work 
 
3.1.8 Vectors 
Table 9. List of vectors and source. 
Name  Source 
pDONR223 entry clone vector Invitrogen 
N-tagged mCherry MaMTH prey vector 
(A1245) 
Built by Dr. Jamie Snider 
C-tagged MaMTH bait vector (A1160) Built by Dr. Jamie Snider  
pOG44 Flp-In recombinase expression 
vector 
Thermo Fisher Scientific 
Vector maps are shown in Supplementary Figures 1S, 2S and 3S. 
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3.1.9 Software and databanks 
Table 10. List of software, company and web address. 
Software Company Web address 
ApE University of 
California, Sun 
http://biologylabs.utah.edu/jorgensen/wayned/ape/  
FpClass Jurisca Lab, IBM Life 
Sciences Discovery 
Centre 
http://dcv.uhnres.utoronto.ca/FPCLASS/ 
NCBI BLAST National Center for 
Biotechonology 
Information 
https://blast.ncbi.nlm.nih.gov/Blast.cgi  
Primer X Bioinformatics.Org http://www.bioinformatics.org/primerx/  
 
3.1.10 Oligonucleotides 
Table 11. List of oligonucleotides, sequence and company. 
Name  Sequence (5’  3’) Company 
ErbB2 attB site 
forward 
GGGGACAAGTTTGTACAAAAAAGCAGG
CTATGGAGCTGGCGGCCTTGTGCCGCT  
EUROFINS MWG 
Operon 
ErbB2 attB site 
reverse 
GGGGACCACTTTGTACAAGAAAGCTGG
GTGCACTGGCACGTCCAGACCCAGGTA
C  
EUROFINS MWG 
Operon 
ErbB2 T798M 
forward 
CGGTGCAGCTGGTGATGCAGCTTATGCC
CTATG  
EUROFINS MWG 
Operon 
ErbB2 T798M 
reverse 
CATAGGGCATAAGCTGCATCACCAGCT
GCACCG  
EUROFINS MWG 
Operon 
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ErbB2 K753A 
forward 
CCAGTGGCCATCGCAGTGTTGAGGG  EUROFINS MWG 
Operon 
ErbB2 K753A 
reverse 
CCCTCAACACTGCGATGGCCACTGG  EUROFINS MWG 
Operon 
SRMS R147A 
forward 
CCTTCCTCATCGCGCCCAGCGAGAG  EUROFINS MWG 
Operon 
SRMS R147A 
reverse 
CTCTCGCTGGGCGCGATGAGGAAGG EUROFINS MWG 
Operon 
ErbB2 
sequencing 
primer from 
1184nt forward 
AGTTTCCAGATGAGGAGGGC 
 
EUROFINS MWG 
Operon 
 
3.2 Methods 
3.2.1 Cell culture 
During cell culture work, good cell culture practices (GCCP) were followed. 
The lab of Dr. Igor Stagljar has generated different HEK 293 reporter cell lines, one subtype 
is B0166, which has stable integrated Gaussia princeps luciferase under the control of a Gal4/UAS 
system. When expressed, Gaussia luciferase is secreted into the media. Stable cell lines of ErbB2 
wild type, ErbB2 ex16del, ErbB2 T798M, ErbB2 K753A, were generated through the FLP-In 
TREx technique in B0166 cell subline as described in “Generation of MaMTH reporter cell lines 
stably expressing baits”. Cell lines are Grip-tite, which means they overexpress the surface protein 
MSR1 that increases the adherence of the cells to tissue culture plates. 
3.2.2 Cell passaging 
Cells were cultured at 37 C under an atmosphere of 5% CO2 in 10 cm culture dishes and in 
culture media, DMEM ((+)4.5 g/L D-Glucose, (+) L-Glutamine, (+) 110 mg/L sodium pyruvate) 
with 10% FBS and 1% penicillin/streptomycin. Cells were passaged when confluent. Old media 
were aspirated, cells were rinsed once with pre-warmed PBS to remove leftover media and 
incubated for 5 min at ambient temperature with 1 ml versene, to weaken the attachment of the 
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cell to surface. The versene was removed and 1 ml of TrypLE was added, plates were incubated 
for 5 min at 37 C  to detach viable cells. Pre-warmed culture medium was added and TrypLE was 
inactivated. The cell suspension was transferred to a new culture dish and diluted with culture 
medium to a final volume of 10 ml. Fresh culture medium was added every three days until cells 
were ready for splitting.  
3.2.3 Cell count 
Cell count was determined with the Coulter Z Counter Series cell counter (particle count and 
size analysers). After treatment with TrypLE and resuspension, 500 µl cell suspension was added 
to 9.5 ml IsoFlow Sheath Fluid in a CasyCup. The cell count program used for HEK 293 cells is 
shown in Table 12. 
Table 12. Set up of the Cell Counter Coulter Z Series. 
Set up 100 µmC 
Kd 65.54 
Select units µm 
Set Upper Size TU 30.00 µm 
Set Lower Size TL 10.00 µm 
count mode between 
 
3.2.4 Generation of MaMTH reporter cell lines stably expressing baits  
Isogenic MaMTH reporter cell lines stably expressing baits of interest were generated using 
the Flp-In TREx system (Thermo Fisher Scientific). HEK 293 B0166 cells (MaMTH reporter 
cells) were grown at 37 C at 5 % CO2 in culture media in 2 ml to 50-60 % confluency. Cells were 
transfected with 900 ng pOG44 and 100 ng of bait construct in A1160 vector using X-tremegene 
9 transfection reagent as per manufacturer instructions. After 5 hr, media containing transfection 
reagent was removed and replaced with fresh culture media. Cells were grown for 48 hr and then 
split 1 in 2 into a new 6-well plate in 2 ml using culture media with 100 µg/ml Hygromycin and 
150 µg/ml Blasticidin until individual foci appeared. Foci were expanded and correct, tetracycline 
induced bait expression was verified by Western blotting.  
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3.2.5 MaMTH Assay 
Day 1: Cell seeding 
Highly confluent (80-100%) cells were washed and treated with TrypLE as above. Cell 
concentration was measured with Coulter Z Series and 10,000 cells per well were seeded in clear, 
flat-bottom, tissue-culture 96 well plate and incubated 18 to 24 hr at 37 C and 5% CO2.  
Day 2: Transfection 
BES-CaCl2 transfection was performed in biological triplicates. Per transfection, 4.5 µl H20, 5 µl 
2 X BES (280 mM), 50 ng prey DNA and 0.5 µl 2.5 M CaCl2 were mixed and incubated for 15 
min at ambient temperature. 10 µl of transfection mix was transferred into each well of a 96 well 
plate, and plates were incubated at 37 C and 5% CO2 for 5 hr. The media was removed and 
replaced with 100 µl of fresh media with tetracycline, plates were incubated overnight at 37 C 
and 5% CO2.  
Day 3: Luciferase assay 
The media were transferred into a new 96 well luminescence plate and diluted in PBS (1:20). The 
luciferase substrate coelenterazine was prediluted in the PBS (17:10,000) and incubated for 30 
mins in the dark. Luciferase activity was measured with Luminoskan Ascent microplate reader 
(Thermo Labsystems) with optimal settings (Table 13). 
Day 4: RFP measurements 
After further incubation at 37 °C overnight, the RFP-Signal was measured with SynergyNeo 
microplate reader (BioTek). 
Table 13.  Luminometers parameters. 
Plate acceleration 10 
Settle delay 1,000 
Blanking time of integration time 100 % 
Dispenser speed settings  
Dispenser 1 30 
Dispenser 2 18 
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Dispenser 3 18 
Dispenser and Measurement 20 µl 
Integration time 100 ms 
 
3.2.5.1  Data analysis 
The relative luciferase signal (RLS) was normalised according to the following formula: 
𝑅𝐿𝑆 (𝑝𝑟𝑒𝑦)−𝑅𝐿𝑆 (𝐿𝑒𝑥𝐴)
𝑅𝐿𝑆 (𝐺𝐴𝐿4)−𝑅𝐿𝑆 (𝐿𝑒𝑥𝐴)
∙ 100%. From each value background luminesce which corresponds to “bait 
only” signal (LexA) was subtracted and interaction intensity was shown as percentage of 
transcription factor GAL4, which has the highest positive signal and determines the maximal 
activity of the assay. 
3.2.6 Site-directed mutagenesis 
Site-directed mutagenesis primers were designed with online tool PrimerX 
(http://www.bioinformatics.org/primerx/) with the specific desired modification for mutation in 
the centre of oligonucleotide (Table 11). Mutagenesis reactions were run according to the 
parameters in Tables 14 and 15. After the PCR, 0.5 µl of DpnI enzyme were added to digest the 
methylated parental DNA and samples were incubated 1 hr at 37 C. An aliquot of PCR reaction 
was mixed with 6x Loading Buffer and samples were loaded on 1% agarose gel. Gel 
electrophoresis was run for 30 min at 100 V, and DNA was visualized with SybrSafe.  The DNA 
was amplified and purified as described in 3.2.7 and 3.2.8, below. DNA sequences were checked 
by Sanger sequencing. 
Table 14. Site directed reaction mix.  
Reagent Volume (µl) 
KAPA (2x) 12.5 
Forward primer (20 mM) 0.5 
Reverse primer (20 mM) 0.5 
DNA template (100 ng/µl) 0.5 
ddH20 11.5  
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Table 15. PCR program for SDM.  
Temperature Time 
95 C 30 sec 
95 C 30 sec x 18 
65 C 30 sec x 18 
72 C 3 min x 18 
72 C 7 min 
4 C ∞ 
 
3.2.7 Transformation through heat shock method 
Highly chemically competent E. coli DH5α were transferred to an ice-cold tube with 1 µl of 
plasmid (or 4 µl of the LR reaction mix). Samples were incubated for 30 min in ice. The tube was 
placed for 1min at 42 C , then again on ice for 2 min. Subsequently, 500 µl LB media were added 
into the tube and cells were incubated for 1 hr at 37 C and shaking 200 rpm. The cells were 
centrifuged for 1 min at room temperature at 14,000 g.  450 µl of supernatant was removed and 
the cell pellet was resuspended in the remaining media and plated on LB agar with antibiotic. The 
plate was incubated at 37 C overnight.  
3.2.8 Purification of the plasmid (Mini Prep) 
A single bacteria colony was picked and incubated in 3 ml of LB + antibiotic at 37 C for 16 
hr and shaking 200 rpm. For the purification of the plasmids, the Presto Mini Plasmid Kit from 
Geneaid was used, according to the manufacturer’s instructions. The concentrations of the DNA 
were determined by NanoDrop spectrophotometry.  
3.2.9 DNA sequencing 
Sequencing was carried out at The Centre for Applied Genomics, Hospital for Sick Children, 
Toronto. The results were monitored and analysed using the freeware ApE and NCBI BLAST.  
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3.2.10 Gateway Cloning 
3.2.10.1 Generation of Entry clones 
Most cDNAs were originally obtained from human ORFeome collection v 8.1 (Stagljar Lab) 
and v 9.1 (Taipale Lab). Bacteria glycerol stocks with the desired entry clones were plated on agar 
plate + antibiotic and left overnight at 37 C. Plasmids were purified by mini-prep (above). DNA 
sequences were check by Sanger sequencing. 
cDNAs that were not in entry clone vectors were cloned into pDONR223 by PCR and Gateway 
BP reactions (Life Technologies) as follows.  Specific primers with Gateway attB1 and attB2 
sequences to the 5’ and 3’ were designed to amplify specific cDNA fragment of interest (Table 
11). A PCR reaction was performed (Table 16 and Table 17), and samples were run on a 1% 
agarose gel; bands of the right size were extracted with GenepHlow Gel/PCR Kit from Geneaid 
according to manufacturer’s protocol. The DNA concentration was measured with the NanoDrop 
spectrophotometry. BP Cloning was performed: 0.5 µl of purified cDNA of interest (100 ng/µl), 
0.5 µl of pDONR223 entry clone vector (150 ng/µl), 3 µl 1xTE Buffer and 0.5 µl of BP Clonase 
II Enzyme Mix were mixed and reaction was incubated for 16 hr at room temperature. After 
incubation, 0.8 µl of Proteinase K was added and incubated 20 min at 37 C. The DNA was 
amplified and purified as described above. DNA sequences were confirmed by Sanger sequencing 
using the M13 forward primer. 
Table 16. PCR reaction mix. 
Reagent Volume (µl) 
KAPA (2x) 25 
Forward primer (50 mM) 1 
Reverse primer (50 Mm) 1 
DNA template (100 ng/µl) 1 
DMSO 2.5 
ddH20 19.5  
 
Table 17.  PCR program. 
Temperature Time 
94C 2 min 
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94 C 30 sec x 18 
65 C 30 sec x 18 
72 C 8 min x 18 
72 C 8 min 
4 C ∞ 
 
3.2.10.2 Cloning genes of interest into MaMTH expression vectors 
Gateway LR Cloning was performed for generation of MaMTH expression vectors. 0.5 µl 
entry clone (100 ng/µl), 0.5 µl of MaMTH destination vector (A1243 or A1160) (150 ng/µl), 3 µl 
1xTE Buffer and 0.5 µl of LR Clonase II Enzyme Mix were mixed and reactions were incubated 
for 16 hr at ambient temperature. After incubation, 0.8 µl of Proteinase K was added and incubated 
20 min at 37 C. The DNA was amplified and purified as described above. DNA sequences were 
checked by Sanger sequencing using the CMV forward primer. 
3.2.11 Western blot  
3.2.11.1 Sample preparation 
DMEM media was removed from tissue plates, and cells were washed with ice cold PBS and 
lysed with cell lysis buffer H plus protease inhibitor. Samples were incubated for 10 min at 4 C 
on the shaker and cells were collected with a pipette tip on ice. The cell lysate was centrifuged for 
15 min at 14,000 g at 4 C and supernatant was collected. 4x sample buffer was add to the 
supernatant and boiled for 5min at 95 C. Samples were stored at -20 C. 
3.2.11.2 Total Protein Assay 
The Thermo Fisher Scientific Pierce BCA Protein Assay Kit was used according to the 
manufacturer’s protocol with some modifications. For calibration and preparation of the standard 
curve, 2 µl dilution of standards 0, 25, 125, 250, 500, 750, 1000, 1500 and 2000 ng/µl albumin 
concentration in ddH2O were added to a 96-well plate. 2 µl of each sample were added to separate 
wells. Working reagent was prepared according to the manufacturer’s protocol and 100 µl were 
added to samples and standards. The plate was incubated at 37 C for 30 minutes. Standards and 
samples were run in triplicate and absorption at 562 nm was measured with the Synergy Neo 
microplate reader from BioTek. 
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3.2.11.3 Western Blots 
Equal amounts of protein were loaded onto 10% SDS-PAGE gels and electrophoresis 
performed. Molecular weights of samples were determined by comparison to PageRuler Prestained 
Protein Ladder. Gels were run with 1x running buffer for 60-70 min at 150V. Proteins were blotted 
onto a nitrocellulose membrane with 0.2 m pore diameter using wet transfer for 90 min at 300 
mA with 1x transfer buffer. Membranes were stained in Ponceau S for 1 min, washed for 1 min 
with 1% acetic acid and then 1 min with water to determine the transfer quality. Prior to blocking, 
membranes were washed in TBST until all Ponceau S was removed. Membranes were blocked for 
1.5 h while shaking in 2% (w/v) BSA. The membranes were incubated in primary antibodies 
(1:10000 or 1:5000 dilution) in TBST overnight, while shaking at 4 C. Membranes were then 
washed 3 x 15 min with TBST while shaking. Secondary antibodies (1:10000 dilution) were 
incubated with the membranes while shaking at ambient temperature for 1.5 h, then membranes 
were washed 3 x 15 min with TBST. The membranes were covered with enhanced 
chemiluminescence (ECL) substrate and film was exposed.  
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4. RESULTS 
4.1 Expression and activation levels of bait proteins  
MaMTH reporter cell lines with stable expression of desired baits have to be validated for bait 
expression after the generation of cell line. The generation of MaMTH expression vectors with 
four different ErbB2 cDNAs was successful and generation of stable integrated ErbB2 proteins in 
B0166 with the FLP-In TREx method was accomplished. The generated cell lines ErbB2 wild type 
(wt), ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A were validated by analysing tetracycline 
(Tet) inducible bait expression by Western blot. Expression and activation of ErbB2 wt bait protein 
were tested in absence of Tet and in the presence of different Tet concentrations (0.1, 0.5 and 1.0 
µg/ml) (Figure 4). Expression and activation of ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A 
baits were tested with Tet (0.5 µg/ml) and without Tet (Figure 5). The antibodies used were anti-
V5 and anti-ErbB2 to measure total bait expression, general phosphotyrosine anti-pY99 and anti-
pErbB2 (Y1221/Y1222) to measure the phosphorylation state of ErbB2, anti-Erk1/2 and anti- 
pErk1/2 to determine activation of the downstream components of ErbB2 mediated signalling, and 
anti-α tubulin as a loading control.  
Expression of all bait proteins was detectable only in presence of Tet using anti-V5 and 
anti-ErbB2 antibodies. Under Tet induction (0.1, 0.5 and 1.0 µg/ml), ErbB2 wt was phosphorylated 
and increased phosphorylation of pErk1/2 was detected. ErbB2 ex16del and ErbB2 T798M 
showed increased phosphorylation of ErbB2 and downstream activation of pErk1/2 with 0.5 µg/ml 
Tet. Phosphorylation of ErbB2 K753A and phosphorylation of Erk1/2 in the same sample were 
not detectable with or without Tet.  
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Figure 4. Expression and activation levels of ErbB2 wild type bait protein. HEK293 B0166 
cells stably expressing ErbB2 wt bait were cultured with different tetracycline concentrations 
overnight to induce bait expression, and proteins of interest were evaluated by Western blot with 
anti-V5 and anti-ErbB2 for bait expression, anti-pY99 to measure phosphorylation state of ErbB2, 
anti-Erk1/2, anti-pErk1/2 to determine activation of the downstream components and anti-α 
tubulin as loading control. Red arrow indicates band for ErbB2 protein.  
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Figure 5. Expression and activation levels of bait proteins were tested by Western blotting. 
HEK293 B0166 cells stably expressing bait proteins were cultured with 0.5 µg/ml and without 
tetracycline overnight. Proteins of interest were evaluated with anti-V5 tag for bait expression, 
anti-pErbB2 (Y1221/Y1222) to measure phosphorylation state of ErbB2, anti-Erk1/2, anti- 
pErk1/2 to determine activation of the downstream components and anti-α tubulin as loading 
control for ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A and ErbB2 wt cell lines. 
 
4.2 MaMTH assay using a small set of positive and non-interactors for optimization 
For further validation of the MaMTH cell lines with stable expression of bait and to determine 
whether 0.5 μg/ml Tet is optimal for bait expression for future experiments, the MaMTH assay 
was performed. Stable cell lines ErbB2 wt, ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A were 
transfected with prey MaMTH vectors expressing: GAL4 transcription factor, Pex7 as negative 
control, Hsp90 as positive control, Shc1 as another known positive interactor and transcription 
factor LexA which is unrelated DNA for “bait only” signal. The interaction levels were measured 
-/+ tetracycline concentration (0.5 µg/ml). Raw luminescence data was normalised and interaction 
signals were shown as percentage of transcription factor. After measurement of luciferase activity, 
Western blot analysis of bait and prey expression was performed to determine if the MaMTH 
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system was working properly. For detection of bait protein anti-V5 was used and for detection of 
prey proteins anti-FLAG was used, anti-α tubulin was used as loading control. MaMTH and 
Western blot results are shown in Figure 6. 
The MaMTH assay with a small reference set of preys for all four cell lines (ErbB2 wt, 
ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A) showed higher signal with Hsp90 and Shc1 
compared to the negative control, Pex7, at a Tet concentration of 0.5 µg/ml. No strong 
luminescence signal was detectable without bait expression (no Tet). As shown by Western blot, 
bait expression was detected only at Tet concentrations of 0.5 µg/ml and prey expression was 
detected in all samples. 
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Figure 6. Normalised luminescence data from MaMTH assay using a small set of preys and 
Western blot analysis of bait and prey expression. MaMTH assay was performed with MaMTH 
reporter cell lines (HEK293 B0166) stably expressing [A] ErbB2 wild type [B] ErbB2 ex16del, 
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[C] ErbB2 T798M and [D] ErbB2 K753A baits transfected with Pex7 as negative control, Hsp90 
as positive control and Shc1 as known interactor. After MaMTH assay, expression of baits and 
preys was tested on Western blot using anti-V5 for bait detection, anti-FLAG for prey detection 
and anti-α tubulin as loading control. Prey proteins are indicated with arrows: Pex7 (red), Hsp90 
(blue) and Shc1 (green). Detected prey proteins size is: ~43 kDa for Pex7, ~ 97 kDa for Hsp90 
and ~70 kDa for Shc1.  Error bars represent standard deviation from 3 biological replicates.   
 
4.3 Screening of the SH2/PTB prey library 
The screening of SH2/PTB domain-containing proteins against ErbB2 wt was performed to 
detect PPIs. For the screen of the SH2/PTB domain-containing proteins, the prey library including 
98 proteins was generated by Gateway cloning into the RFP N-tagged MaMTH prey vector 
(designated A1245) by members of Stagljar Lab (Supplementary Table 1S). HEK 293 B0166 
ErbB2 wt cells were transfected with SH2/PTB library prey vectors, with transcription factors 
GAL4 and LexA for normalization purposes and with positive control Shc1 and negative control 
Pex7. Expression of bait was induced with 0.5 µg/ml Tet. One day after transfection, luminescence 
was measured and raw data was normalised as described above (Figure 7). Two days after 
transfection, RFP fluorescence was measured to determine prey expression. The background 
fluorescence (results from cells transfected with unrelated DNA, LexA) was subtracted from 
sample RFP data, and samples with lower signal than background were removed from the screen 
results as these preys were considered not to be expressed. The list of SH2/PTB library preys and 
corresponding RFP values is shown in Supplementary Table 2S. Figure 7 shows normalised 
luminescence data of the 85 expressed proteins from the SH2/PTB prey library, sorted from lowest 
to the highest value.  Table 18 shows 36 detected ErbB2 interactors from the SH2/PTB prey library 
with score higher than 5,40% of TF, and indicates the 18 that are already known interactors of 
ErbB2 (information from BioGRID database: (https://thebiogrid.org/). For unknown interactors, 
FpClass predictions of interactions were calculated and score is indicated 
(http://dcv.uhnres.utoronto.ca/FPCLASS/). 
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Figure 7. Normalised luminescence data from screen of the SH2/PTB prey library with ErbB2 wt stably expressed in HEK293 
B0166. Error bars represent standard deviation across 3 biological replicates. Red line indicates 5,4% cut-off threshold.  
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Table 18. List of detected ErbB2 interactors from SH2/PTB prey library with corresponding 
score (% of TF signal). Known interactors from BioGRID database ( https://thebiogrid.org/ ) and 
FpClass (http://dcv.uhnres.utoronto.ca/FPCLASS/) predicted interactors with score are indicated. 
Protein Score Known 
interactor  
FpClass 
score 
 
Protein Score Known 
interactor  
FpClass 
score 
CSK 5.4 
 
0.8826 
 
CLNK 17.65 +  
 
DOK6 5.7 +    SH2D1A 17.72  0.3442 
SH2D4B 5.8 
   
SH2D1B 21.39 +  
 
TNS3 6.55 + 
  
STAT6 22.12 
 
0.3061 
YES1 7.24 
 
0.8826 
 
ZAP70 24.04 
 
0.8826 
CRKL 7.97 + 
  
CBL 24.32 + 
 
SH2D3A 9.53 +    SLA 25.05 +   
STAT3 9.89 + 
  
CHN2 26.17 
 
0.4875 
SOCS3 10.47 
 
0.8826 
 
SYK 28.79 +  
 
STAT5B 10.75 
 
0.8826 
 
STAPI 30.26 
 
0.769 
SH2D2A 10.97 +    FYN 32.42  0.8826 
GRB2 11.96 + 
  
CRK2 33.76 +  
 
TNS4 13.15 
 
0.7991 
 
DOK2 34.28 
 
0.8826 
SOCS2 15.3 
 
0.7376 
 
SRMS 43.35 
 
0.8203 
SOCS1 15.36 +  
  
SHD 51.48 
 
0.7991 
DOK1 16.18 +  
  
NCK2 55.71 + 
 
RIN3 16.58 
 
0.7738 
 
SLA2 69.88 +  
 
DOK7 16.83 
 
0.512 
 
SHC1 86.13 + 
 
 
4.4 MaMTH assay using a small set of proteins containing SH2 domain mutation 
Predicted interaction of phosphotyrosines with SH2 domains requires a conserved SH2 domain 
arginine residue. To determine the importance of these residues in interactions with ErbB2, a 
MaMTH assay was performed. Prior to the MaMTH assay, SHD R265A, SLA2 R143A, Crk2 
R38A and SRMS R147A mutant proteins were generated by site-directed mutagenesis and 
Gateway cloned into the A1245 RFP N-tagged MaMTH prey vector, by members of Stagljar lab. 
HEK 293 B0166 ErbB2 wt cells were transfected with transcription factors GAL4 and LexA for 
normalization, Shc1 and Pex7 as positive and negative controls, and SHD, SHD R265A, SLA2, 
SLA2 R143A, Crk2, Crk2 R38A, SRMS and SRMS R147A preys to test interactions between wt 
and mutant preys and ErbB2 wt. Expression of bait was induced with 0.5 µg/ml Tet. One day after 
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transfection, luciferase activity was measured and cell lysates were collected for Western blot 
analysis of bait and prey expression. Figure 8 shows luminescence signals normalized as described 
above. P-values were measured compared to corresponding controls with two-tailed unpaired t-
test. Western blot analysis of bait and prey expression was performed. For detection of bait protein 
anti-V5 was used, and for detection of prey proteins anti-FLAG was used, while α tubulin was 
used as loading control (Figure 9).  
The MaMTH assay with a small set of proteins containing SH2 domain mutation with 
ErbB2 wt showed positive interaction for all preys except Pex7 and SRMS R147A. Western blot 
analysis showed ErbB2 wt bait expression in all samples and expression of all preys except SRMS 
R174A. 
 
 
Figure 8. Normalised luminescence data from MaMTH assay using a small set of proteins 
containing SH2 domain mutation expressed in HEK 293 B0166 ErbB2 wt. Error bars represent 
standard deviation across 3 biological replicates. *P < 0.05; two-tailed unpaired t-test calculations 
compared to corresponding controls. 
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Figure 9. Western blot analysis of bait and prey expression after MaMTH assay using anti-
V5 for bait detection, anti-FLAG for prey detection and α tubulin as loading control. Detected prey 
proteins size is: ~70 kDa for Shc1, ~43 kDA forPex7, ~51 kDa for SHD and SHD R265A, ~35 
kDa for SLA2 and SLA2 R143A, ~ 49 kDa for Crk2 and Crk2 R38A and ~63 kDa for SRMS.  
 
4.5 Screening of the SH2/PTB hits against ErbB2 mutants 
The MaMTH assay was performed for functional characterisation of interactions between 
ErbB2 and detected interactors from SH2/PTB prey library. Twenty-four of 36 detected interacting 
preys (Supplementary Table 3S) were randomly selected and transfected into HEK 293 B0166 cell 
lines with stable expression of ErbB2 wt, ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A baits. 
GAL4 and LexA preys were also transfected for normalization and Pex7 as negative control. Bait 
expression was induced with 0.5 µg/ml Tet and luminescence was measured. The luminescence 
signals are presented as percentage of transcription factor (TF) and P-values were measured 
compared to corresponding wild type controls with two-tailed unpaired t-test (Figures 10). 
The MaMTH assay with 24 detected interactors from SH2/PTB prey library and all four 
cell lines (ErbB2 wt, ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A) showed positive 
interaction signal for all tested prey proteins. Statistical significance of the differences in 
interaction signals were calculated and corresponding P values are provided. Eight of 24 tested 
proteins with ErbB2 ex16del and 15/24 tested proteins with ErbB2 T798M showed significantly 
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higher interaction signals compared to ErbB2 wt (Table 19). ErbB2 K753A and tested preys did 
not show different interaction signals compared to ErbB2 wt.  
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[A]
 
[B] 
 
Figure 10. Normalised luminescence data from MaMTH assay with 24 detected ErbB2 hits from SH2/PTB prey library against 
[A] ErbB2 wt, ErbB2 ex16del and ErbB2 T798M and [B] ErbB2 wt and ErbB2 K753A stably expressed in HEK 293 B0166. 
Error bars represent standard deviation across 3 biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001 two-tailed unpaired t-test 
calculations compared to corresponding wild type controls. 
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Table 19. List of ErbB2 hits from SH2/PTB that showed significantly higher interactions 
signal with ErbB2 ex16del and ErbB2 T798M compared to ErbB2 wt and corresponding P 
values.  
Protein ErbB2 ex16del  
P value 
ErbB2 T798M  
P value 
CRKL  < 0.001 
CSK  < 0.01 
GRB2 < 0.05 < 0.001 
NCK2  < 0.001 
SH2D1A < 0.01 < 0.001 
SH2D1B < 0.05  
SH2D4B < 0.05 < 0.01 
SCH1 < 0.05 < 0.001 
SHD  < 0.001 
SLA2 < 0.05  
SOCS3  < 0.001 
SRMS  < 0.05 
STAT5B  < 0.05 
ZAP70 < 0.05  
CRK2 < 0.01 < 0.001 
DOK2  < 0.001 
CHN2  < 0.01 
DOK7  < 0.01 
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5. DISCUSSION  
5.1 Expression levels of ErbB2 wild type bait with different tetracycline levels 
MaMTH reporter cell lines were designed to have tetracycline regulated bait expression, which 
alows bait expression levels to be better regulated and equalized, making resulting data more 
comparable. HEK 293 B0166 cell line stably expressing ErbB2 wt protein upon tetracycline 
induction showed equal bait expression with 0.1, 0.5 and 1.0 µg/ml tetracycline (Figure 4) by 
Western blot. Determination of optimal expression with ErbB2 in an active state was important 
for the next experiments of mapping the interactome. ErbB2 activation was shown by increased 
pY99 signal with 0.1, 0.5 and 1.0 µg/ml tetracycline. The anti-pY88 is a general phospho-tyrosine 
antibody, and is not specific for the phosphorylation of ErbB2. Phosphorylation was detected for 
ErbB2 bait with tetracycline and with 1.0 µg/ml it was slightly higher that with 0.1 and 0.5 µg/ml. 
Because of the ability of anti-pY99 to detect many phosphorylated tyrosines in different proteins, 
it would be better to use specific pErbB2 antibody to determine if ErbB2 is more active with 1.0 
µg/ml tetracycline. The downstream activation of the MAPK-kinase pathway, which is activated 
through ErbB receptor kinase family (Wieduwilt and Moasser, 2008), was detected with the 
phosphorylation of Erk1/2 at same level with bait expression at 0.1, 0.5 and 1.0 µg/ml tetracycline. 
0.5 µg/ml tetracycline was chosen for future experiments as suitable contraction for bait expression 
and activation because with all tested tetracycline concentrations the same expression level of bait 
was detected alongside the same level of Erk1/2 activation.   
 
5.2 Characterization of ErbB2 mutant baits 
ErbB2 ex16del is a transcript variant of ErbB2 protein that occurs naturally but rarely, has 
increased ligand-independent activity and significantly increased tyrosine phosphorylation 
compared with ErbB2 wt (Moasser, 2007; Jackson et al., 2013; Turpin et al., 2016). ErbB2 T798M 
is an oncogenic version that has increased affinity for ATP stabilizing an active protein 
conformation. Compared with ErbB2 wt, ErbB2 T798M has increased autocatalytic activity 
(Rexer et al., 2013). ErbB2 K753A is expected to have impaired kinase activity. Residue K753 in 
the ATP binding pocket has been identified as important for ErbB2 activation, through formation 
of a salt bridge with E770, which is one of the most crucial interactions for kinase activation 
(Aertgeerts et al., 2011). HEK 293 B0166 cell lines with stable expression of ErbB2 ex16del, 
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ErbB2 T798M and ErbB2 K753A were tested by Western blot to validate expression and 
activation levels. Expression of all three mutant ErbB2 baits was induced with 0.5 µg/ml 
tetracycline, while expression was not detectable without tetracycline (Figure 5). Phosphorylation 
of baits were tested with anti-pErbB2 antibody that specifically detects phosphorylation of 
tyrosines at position 1221 and 1222. Phosphorylation was detected for ErbB2 ex16del and ErbB2 
T798M and was lower than that of ErbB2 wt. ErbB2 K753A did not show phosphorylation at these 
particular tyrosine residues. To check downstream activation of signalling pathways, 
phosphorylation of Erk1/2 was determined. Without tetracycline, endogenous levels of Erk1/2 
were detected, and upon tetracycline induction, the ErbB2 baits showed different levels of pErk1/2. 
ErbB2 ex16del and ErbB2 T798M promote increased Erk1/2 phosphorylation compared to ErbB2 
wt, while pErk1/2 level did not increase above background levels upon ErbB2 K753A expression. 
Expressed ErbB2 ex16del and ErbB2 T798M get phosphorylated which leads to their activation 
and activation of downstream MAPK-kinase pathway what was expected and has been shown by 
Castiglioni et al. (2006) and Rexer et al. (2013). ErbB2 K753A can be considered as less kinase 
active compared to ErbB2 wt since it was not phosphorylated at Y1221 and Y1222 as it has been 
shown previously in COS-7 cells (Xu et al., 2001) and increased pErk1/2 was not detectable. These 
data indicate that 0.5 µg/ml tetracycline was suitable to induce bait expression in all ErbB2 baits.  
 
5.3 Initial MaMTH assay with a small set of positive and negative interactors 
To further validate the tetracycline concentration of 0.5 µg/ml for bait expression, a MaMTH 
assay with a small subset of preys for all HEK 293 B0166 ErbB2 cell lines was performed -/+ 
tetracycline (0.5 µg/ml). Pex7 was chosen as negative control because has not been reported to 
interact with the ErbB2. Hsp90 and Shc1 were chosen as positive controls. Hsp90 is molecular 
chaperone that promotes protein maturation into an active and stable conformation and is involved 
in maintenance of the mature form of proteins. It has been shown ErbB2 is dependent upon Hsp90 
for its stability through the whole life span of the receptor (Citri et al., 2004). Shc1 is a signalling 
adapter protein that binds ErbB2 through its PTB domain (Wagner et al., 2013). ErbB2/Shc1 and 
ErbB2/Hsp90 interactions have been already shown in MaMTH (Petschnigg et al., 2014; Yao et 
al., 2017). MaMTH luminescence signal is proportional to interaction between bait and prey 
(Petschnigg et al., 2014; Saraon et al., 2017). Without tetracycline, interactions were not detected 
between ErbB2 baits and positive controls. Upon tetracycline induction ErbB2 wt, ErbB2 ex16del, 
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ErbB2 T798M, ErbB2 K753A showed positive interactions with known interactors Hsp90 and 
Shc1 and no interactions with Pex7 (Figure 6).  Additionally, Western blot analysis showed bait 
expression only with 0.5 µg/ml tetracycline, while comparable levels of prey expression were 
detectable in the presence and absence of tetracycline, which demonstrates that the luciferase 
signal is produced upon genuine interactions between bait and prey. By considering the results 
from the Western blots and the MaMTH data, the concentration of 0.5 µg/ml tetracycline is suitable 
for induction of bait expression and detection of protein-protein interactions. Therefore, further 
experiments with all four baits (ErbB2 wt, ErbB2 ex16del, ErbB2 T798M, ErbB2 K753A) were 
performed with a tetracycline concentration of 0.5 µg/ml.  
 
5.4 Screening of the SH2/PTB prey library against ErbB2 wt 
The MaMTH assay is useful method for high throughput screens. A threshold cut-off between 
positive and negative interactions has to be determined, such that every interaction which shows a 
higher signal than the threshold can be considered to be a hit. In this screen, the luminescence 
signal of the negative control/non-interactor Pex7 was lower than 2% of that of the transcription 
factor. Therefore, a score of 5,40% of the signal of the transcription factor was used as cut-off 
assuming that interaction signals higher than 5,4% is positive signal. Proteins that meet the criteria 
are listed in Table 18. There are 36 detected proteins from the SH2/PTB prey library that showed 
positive interaction signals with ErbB2 wt; 18 are already known ErbB2 interactors according to 
BioGRID database (https://thebiogrid.org). Fifteen of the known interactors have been reported 
once using high-throughput approaches based on protein microarrays (Jones et al., 2006), and 
many ErbB2 interactions have not been functionally characterized. The data presented in this thesis 
show that the MaMTH assay can be used for validation of previously found interactors. For Cbl, 
Stat3 and Grb2, function has been established in the context of ErbB2 signalling. Cbl is E3-
ubiquitin ligase, a negative regulator that binds to phosphorylated ErbB1 for ubiquitination and 
lysosomal targeting. Cbl was found to stimulate ErbB2 degradation following its overexpression 
(Klapper et al., 2000). Stats (signal transducer and activator of transcription) are latent 
transcription factors which have been found constitutively active in many human tumors. It has 
been shown that JAK2 (Janus kinase 2) and Stat3 associate with ErbB2 prior to its 
phosphorylation, and ErbB2 activates Stat3 through JAK2 and Src (Ren and Schaefer, 2002). Grb2 
(Growth factor receptor bound protein 2) is a well known adaptor protein, that is recruited to active 
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ErbB family members to activate MAP kinase and PI3K signalling pathways (Schlessinger and 
Lemmon, 2003; Roskoski, 2014). ErbB2 interactions with Cbl, Stat3 and Grb2 were confirmed by 
MaMTH in this experiment. Fifty of 95 total proteins in the SH2/PTB prey library have been 
previously reported as ErbB2 interactors, and 36% of interactors were confirmed with MaMTH. 
The fact that all of the previously known interactors were not identified by MaMTH can be 
explained in part by lack of expression of six of the known interactors (no RFP signal). Another 
reason could be that all the prey proteins were N-tagged with Nub, and the tag could have had an 
influence on the protein folding or interrupted the specific interaction. To decrease the possible 
influence of the N-tag, the C-tagged versions of the preys should also be tested.  
Eighteen proteins showed a positive signal with ErbB2 and have not been previously reported 
as ErbB2 interactors. According to FpClass prediction, 17 of them are predicted interactors (Table 
18). For some novel interactors of ErbB2, connections with ErbB1 have previously been reported. 
For instance, DOK (downstream of tyrosine kinase) proteins are adaptors proteins that regulate 
tyrosine kinase signalling. DOK2 is phosphorylated after ErbB1 activation and suppresses Src, 
AKT and ERK phosphorylation after EGF stimulation. DOK2 has been identified as human lung 
tumor suppressor gene  (Berger et al., 2013). Fyn is an effector of oncogenic ErbB1 signalling in 
glioblastoma that belongs to Src family tyrosine kinase. The active ErbB1 mutant phosphorylates 
and associates with Src and Fyn, significantly promoting tumour cell growth, migration and 
invasion (Lu et al., 2009). The roles of DOK2 or Fyn in ErbB2 signalling still remain to be 
discovered. CHN2, also known as β2-chimaerin, is a GTPase-activating protein that has been 
linked with breast cancer as tumour suppressor. Studies in breast cancer cells demonstrated that 
β2-chimaerin inhibits proliferation downstream of the ErbB2 receptors (Casado-Medrano et al., 
2016). Direct PPI between ErbB2 and CHN2 has not been established until now. SRMS (Src-
related kinase lacking C-terminal regulatory tyrosine and N-terminal myristoylation sites) is 
nonreceptor tyrosine kinase whose cellular role is unknown. It has been reported that SRMS is 
overexpressed in the majority of breast cancer cell lines and expressed at a higher level in breast 
cancers compared to normal mammary tissue (Goel et al., 2013). Since ErbB2 is overexpressed in 
20-30% of breast cancers (Roskoski, 2014), additional characterisation of ErbB2 and SRMS 
interaction may be interesting. The error bars are large in some of the proteins around the cut-off, 
which suggests the presence of some false positives and negatives. Another control experiment 
that could be considered in order to eliminate unspecific binding, is the testing of interactions in 
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the presence of specific tyrosine kinase inhibitors. Tyrosine kinase inhibitors bind to receptors and 
disable receptor activation and PPIs, therefore the MaMTH interaction signal would decrease for 
specific interactions. Further confirmation of novel hits should be done with another approach for 
analysing protein-protein interactions. So far, luminescence-based mammalian interactome 
(LUMIER) assay, co-immunoprecipitation (IP) and mass spectrometry (MS) have been used for 
validation of  MaMTH-detected interactors in previous studies (Petschnigg et al., 2014, 2017; Yao 
et al., 2017).  
RFP fluorescence was measured to confirm prey expression, because RFP expression has been 
shown to correlate with protein expression. Although it is possible to normalize the positive 
interactions to the expression of RFP, to reduce variation in reporter signal resulting from 
differences in prey expression level, in this case it was not necessary to do it because no exact 
determination or comparison of interactions was performed.  
In addition to the 98 proteins included in the SH2/PTB prey library, 25 proteins that contain 
SH2 or PTB domains were missing due to availability in ORFeome collections etc.. To fully map 
the interactome of ErbB2 with SH2/PTB domain containing proteins, the additional proteins 
should be tested. Fifteen of the missing proteins have been reported as ErbB2 interactors 
(Supplementary Table 4S). These include Vav2, a guanine nucleotide exchange factor for the Rho 
family of GTPases, whose recruitment increases metastatic properties and survival of ErbB2 
overexpressing cells (Wang et al., 2006), and PLCγ  involved in tumour invasion  after activation 
through ErbB2 (Wang et al., 2006). Mapping and characterisation of the interactome of ErbB2-
SH2/PTB domain containing proteins can aid understanding of molecular mechanisms of cancer 
biology. The BioGRID database currently shows 200 unique interactors of ErbB2, and the FpClass 
algorithm predicts 1056 interactions for ErbB2, so the ultimate goal is to map all ErbB2 
interactions of human proteome. To accomplish this, an unbiased screen of total human ORFeome 
should be considered.  
 
5.5  Validation of SH2 domain binding in MaMTH  
SH2 domains have a conserved amino acid sequence, the FLVR motif, with a critical arginine 
residue that binds the phosphotyrosines of the ErbB proteins and other RTKs (Wagner et al., 2013). 
Hence, mutating arginine to alanine causes SH2 domain binding ability to phosphotyrosines to 
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decrease. The MaMTH assay can be used for functional characterisation of PPIs. To examine 
whether the SH2 domain of SHD, Sla2, Crk2 and SRMS is critical for interaction with ErbB2, a 
MaMTH assay was performed. Figure 8 shows that significantly lower interaction signals were 
detected for Sla2 R1431A and Crk2 R38A compared to Sla2 wt and Crk2 wt. Western blot analysis 
of bait and prey expression showed equal level of bait expression in all samples except in one 
where Crk2 R38A was expressed. This can be explained that α tubulin showed also lower protein 
level which is probably caused by lower proteins loading in this particular sample. Expression of 
preys has remained comparable in all sample as well. These data indicated that ErbB2-Sla2 and 
ErbB2-Crk2 interactions happen through SH2 domain because the binding of SH2 domain mutants 
to ErbB2 is significantly lower. To further analyse which phosphotyrosine residues are implicated 
in these interactions, ErbB2 tyrosine mutants should be generated and tested in MaMTH. Sla2/ 
Huntingtin Interacting Protein 1, one of the top interactors of ErbB2, is involved in linking the 
endocytic machinery to the actin cytoskeleton (Engqvist-Goldstein et al., 1999). ErbB2-Sla2 
interactions has been reported once (Jones et al., 2006), but no functional studies have been 
published so far. Crk2 is an adaptor protein that regulates cytoskeletal reorganisation for cell 
growth and motility (Roskoski, 2014). ErbB2 facilitates cell invasion though assembly of a 
CAS/Crk2 signalling complex which is necessary for cell migration mediate by ErbB family 
(Spencer et al., 2000). Of the other two tested proteins, SHD R265A did not show significantly 
lower interaction signal, and SRMS R147A was not detected by Western blot (Figure 9). It is 
possible that the SH2 domain is not critical for SHD binding to ErbB2. SRMS binding through the 
SH2 domain was not validated because of the lack of expression of the SRMS R147A prey. 
Possible explanations could be that SRMS R147A is not stable, but this is unlikely because 
expression of this has been reported by Goel et al. (2013), therefore the reason could be that the 
vector or promotor region could have a defect. Overall, the MaMTH assay was shown as a useful 
approach for characterisation of SH2 domain binding and same approach should be used for testing 
binding specificity of other detected ErbB2 hits containing SH2 domains.   
 
5.6  MaMTH interaction characterization of ErbB2 interactors from SH2/PTB prey 
library against ErbB2 mutants 
To validate ErbB2 hits from the SH2/PTB prey library, ErbB2 mutants were generated. ErbB2 
ex16del and ErbB2 T798M are catalytically more active than wild type, and signal-independent 
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phosphorylated receptors. Active mutants should provide the same hits from the screen as did the 
wild type so that the data can be further validated and hits confirmed or refuted. Figure 10 [A] 
shows that 24 tested hits that were previously detected in the screen showed positive interaction 
signal with ErbB2 ex16del and ErbB2 T798M, as was expected. Additionally, remaining 12 hits 
that were detected in the screen should be tested in the same way.    
MaMTH data shows differential interaction profiles for eight prey proteins that strongly bind 
to ErbB2 ex16del and 15 prey proteins that strongly bind to ErbB2 T798M compared with ErbB2 
wt (Table 19). These results indicate that mutant receptors preferentially bind proteins that can be 
involved in aberrant signalling. For instance, ErbB2 ex16del selectively activates Stat3 
transcription factor, which leads to upregulation of Stat3 target genes that are important modulators 
of immune microenvironment (Ren and Schaefer, 2002). Grb2, Shc1 and Crk2 strongly interact 
with both active mutants, and they can have important roles in promoting oncogenic changes.  
Grb2 and Shc1 are adaptor proteins involved in MAPK kinase activation which leads to cell 
proliferation (Roskoski, 2014). Interactions with constantly active receptors may prolong 
activation of downstream MAP kinase. Previously, it has been shown that Crk2 binds ErbB1 active 
mutant L858R and it was suggested that Crk2 has a role in cell survival and oncogenic signalling 
(Petschnigg et al., 2014). Further analysis of these interactions can help in the development of new 
drug therapies to treat diseases associated with ErbB2 receptor tyrosine kinase.  
Another hypothesis was to generate the inactive mutant, which is the kinase dead version of 
the protein. Disabling the ability for auto-phosphorylation, it is possible to detect proteins which 
interact independently from the phosphorylation state of the receptor. ErbB2 K753A has been 
shown in literature to have impaired kinase activity. Testing 24 ErbB2 hits from the SH2/PTB 
library did not change the MaMTH signal with ErbB2 K753A compared to ErbB2 wt (Figure 10 
[B]). It could be that these proteins do not bind in a phosphorylation dependent manner, or that 
kinase activity of ErbB2 K753A is not completely abolished due to its overexpression in this 
system. It is also possible that the tested proteins bind ErbB2 before its activation, like Src kinase 
that does not associate with any of the phosphotyrosine residues in the C terminal tail of ErbB2 
(Kim et al., 2005). To find which proteins interact only with phosphorylated receptor, the ErbB2 
D845A mutant could be tested. The D845 residue is the catalytic aspartate, one of two key residues 
required for kinase activity (Aertgeerts et al., 2011).  
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6. CONCLUSION  
 
This thesis gives insight into the ErbB2-SH2/PTB domain interactome and confirms the power 
of the MaMTH assay to map and characterize protein-protein interactions. First, the MaMTH 
reporter cell lines with stable integration of bait proteins ErbB2 wild type, ErbB2 ex16del, ErbB2 
T798M and ErbB2 K753A were successfully generated and validated. A suitable tetracycline 
concentration for induction of bait expression and its activation status were determined. All cell 
lines were tested by MaMTH assay with a small set of positive and negative interactors. Only 
protein-protein interaction with positive controls were detected, which led to the conclusion that 
the system works properly and the MaMTH assay is suitable to study protein-protein interactions 
in the desired cell lines. Furthermore, the screen of the SH2/PTB prey library with ErbB2 wild 
type was performed to map the ErbB2-SH2/PTB domain interactome. Thirty-six interaction 
partners were determined: 18 novel interactors and 18 known interactors. SHD, Sla2, Crk2 and 
SRMS binding through the SH2 domain to ErbB2 was characterized. Results indicate that SH2 
domains of Sla2 and Crk2 mediate ErbB2-Sla2 and ErbB2-Crk2 interactions. Twenty-four 
identified ErbB2 interactors were further validated in cell lines stably expressing ErbB2 ex16del, 
ErbB2 T798M and ErbB2 K753A, and all of them showed that they interact with mutant ErbB2 
proteins. This data confirms the specificity of detected interactions and shows preferential binding 
of eight proteins to ErbB2 ex16del and 15 proteins to ErbB2 T798M compared to ErbB2 wild type. 
The presented work is aimed at contributing to a better understanding of protein-protein 
interactions with the ErbB2 receptor tyrosine kinase. It revealed novel interactors whose functions 
remain to be characterized and implies the possibility that some protein interactions are involved 
in aberrant signalling pathways.  These findings can be important for future design of new 
therapeutics that target specific protein-protein interactions associated with development of 
disease.  
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8. SUPPLEMENTARY 
8.1 Vectors 
 
 
Figure 1S. pDNOR233 vector. 
 
 
 
 
 
Figure 2S. N-tagged mCherry MaMTH prey vector (A1245). 
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Figure 3S. C-tagged MaMTH bait vector (A1160). 
 
8.2 SH2/PTB Library 
Table 1S. List of the whole SH2/PTB prey library with full name, size and source. Information 
from genecard: http://www.genecards.org/ (accessed January, 14th 2017).  
Gene Full name Size [kDa] Source 
ABL1 ABL Proto-Oncogene 1, Non-
Receptor Tyrosine Kinase  
122.9 ol 
ABL2 ABL Proto-Oncogene 2, Non-
Receptor Tyrosine Kinase 
128.9 ol 
BCAR3 Breast Cancer Anti-Estrogen 
Resistance 3 
92.6 ol 
BLK BLK Proto-Oncogene, Src Family 
Tyrosine Kinase  
57.7 ol 
BLNK B-Cell Adapter Containing A SH2 
Domain Protein  
50.5 ol 
BMX BMX Non-Receptor Tyrosine 
Kinase  
78.0 ol 
BTK Bruton Tyrosine Kinase  76.2 ol 
CBL Cbl Proto-Oncogene 99.8 entry clone 
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CBLB Cbl Proto-Oncogene B 109.5 ol 
CBLC Cbl Proto-Oncogene C 52.5 ol 
CHN1 Rho GTPase-Activating Protein 
2/Chimerin 1 
53.2 ol 
CHN2 Chimerin 2 53.9 hORF 9.1 
CISH Cytokine Inducible SH2 
Containing Protein  
28.7 ol 
CLNK Cytokine Dependent 
Hematopoietic Cell Linker  
49.6 MCG /PCR 
CRK CRK Proto-Oncogene, Adaptor 
Protein 
33.8 ol 
CRK2 CRK Proto-Oncogene, Adaptor 
Protein 2 
42.0 entry clone 
CRKL CRK Like Proto-Oncogene, 
Adaptor Protein  
33.8 ol 
CSK C-Src Tyrosine Kinase  50.7 ol 
DAPP1 Dual Adaptor of Phosphotyrosine 
And 3-Phosphoinositides 1 
32.3 ol 
DOK1 Docking Protein 1 52.4 hORF 8.1 
DOK2 Docking Protein 2 45.4 entry clone 
DOK3 Docking Protein 3 53.3 hORF 8.1 
DOK4 Docking Protein 4 37 entry clone 
DOK6 Docking Protein 6 38.3 entry clone 
DOK7 Docking Protein 7 53.1 hORF 9.1 
FER FER Tyrosine Kinase 94.6 ol 
FES FES Proto-Oncogene, Tyrosine 
Kinase  
93.5 ol 
FGR FGR Proto-Oncogene, Src Family 
Tyrosine Kinase  
59.5 ol 
FRK Fyn Related Src Family Tyrosine 
Kinase  
58.3 ol 
FYN FYN Proto-Oncogene, Src Family 
Tyrosine Kinase  
60.8 hORF 9.1 
GRAP2 GRB2-Related Adaptor Protein 2 37.9 ol 
GRAPL GRB2 Related Adaptor Protein 
Like  
13.4 ol 
GRB10 Growth Factor Receptor Bound 
Protein 10  
67.2 ol 
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GRB14 Growth Factor Receptor Bound 
Protein 14  
60.9 ol 
GRB2 Growth Factor Receptor Bound 
Protein 2  
25.2 ol 
GRB7 Growth Factor Receptor Bound 
Protein 7 
59.6 ol 
HCK HCK Proto-Oncogene, Src Family 
Tyrosine Kinase  
59.6 ol 
HSH2D  Hematopoietic SH2 Domain 
Containing 
 39.0 ol 
IRS2 Insulin Receptor Substrate 2 137.3 MCG/PCR 
ITK IL2 Inducible T-Cell Kinase 71.8 ol 
LCK LCK Proto-Oncogene, Src Family 
Tyrosine Kinase  
58 ol 
LCP2 Lymphocyte Cytosolic Protein 2 60.2 ol 
LYN LYN Proto-Oncogene, Src Family 
Tyrosine Kinase  
58.6 ol 
MATK Megakaryocyte-Associated 
Tyrosine Kinase  
56.5 ol 
NCK1 NCK Adaptor Protein 1 42.9 ol 
NCK2 NCK Adaptor Protein 2 42.9 ol 
PIK3R1 Phosphoinositide-3-Kinase 
Regulatory Subunit 1  
83.6 ol 
PIK3R2 Phosphoinositide-3-Kinase 
Regulatory Subunit 2 
81.5 ol 
PIK3R3 Phosphoinositide-3-Kinase 
Regulatory Subunit 3 
54.4 ol 
PTPN11 Protein Tyrosine Phosphatase, 
Non-Receptor Type 11 
68.4 ol 
PTPN6 Protein Tyrosine Phosphatase, 
Non-Receptor Type 6 
67.6 ol 
RASA1 RAS P21 Protein Activator 1 116.4 ol 
RIN1 Ras And Rab Interactor 1 84.1 ol 
RIN2 Ras And Rab Interactor 2  100.2 hORF 9.1 
RIN3 Ras And Rab Interactor 3  107.8 ol 
SH2B1 SH2B Adaptor Protein 1 79.4 ol 
SH2B2 SH2B Adaptor Protein 2 67.7 ol 
SH2B3 SH2B Adaptor Protein 3  63.2 ol 
SH2D1A SH2 Domain Containing 1A  14.2 ol 
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SH2D1B SH2 Domain Containing 1B  15.3 ol 
SH2D2A SH2 Domain Containing 2A  42.9 ol 
SH2D3A SH2 Domain Containing 3A 63.1 ol 
SH2D3C SH2 Domain Containing 3C  94.4 ol 
SH2D4A SH2 Domain Containing 4A 52.7 ol 
SH2D4B SH2 Domain Containing 4B  51.2 ol 
SH3BP2 SH3 Domain Binding Protein 2 62.2 ol 
SHB SH2 Domain Containing Adaptor 
Protein B  
55.0 ol 
SHC SHC Adaptor Protein 1  62.8 ol 
SHC3 SHC Adaptor Protein 3 64.1 ol 
SHC4 SHC Adaptor Protein 4 68.8 ol 
SHD Src Homology 2 Domain 
Containing Transforming Protein 
D 
38.3 ol 
SHF Src Homology 2 Domain 
Containing F 
46.8 ol 
SLA Src-Like-Adaptor 31.2 ol 
SLA2 Src Like Adaptor 2 28.6 ol 
SOCS1 Suppressor of Cytokine Signaling 
1 
23.6 ol 
SOCS2 Suppressor of Cytokine Signaling 
2 
22.2 ol 
SOCS3 Suppressor of Cytokine Signaling 
3 
24.8 ol 
SOCS4 Suppressor of Cytokine Signaling 
4 
50.6 ol 
SOCS5 Suppressor of Cytokine Signaling 
5 
61.2 ol 
SOCS6 Suppressor of Cytokine Signaling 
6 
59.5 ol 
SRC SRC Proto-Oncogene, Non-
Receptor Tyrosine Kinase 
59.8 ol 
SRMS Src-Related Kinase Lacking C-
Terminal Regulatory Tyrosine 
And N-Terminal Myristylation 
54.5 ol 
STAP1 Signal Transducing Adaptor 
Family Member 1 
34.3 ol 
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STAT1 Signal Transducer and Activator 
of Transcription 1 
87.3 ol 
STAT2 Signal Transducer and Activator 
of Transcription 2 
97.9 ol 
STAT3 Signal Transducer and Activator 
of Transcription 3 
88.1 ol 
STAT4 Signal Transducer and Activator 
of Transcription 4 
85.9 ol 
STAT5A Signal Transducer and Activator 
of Transcription 5A 
90.6 ol 
STAT5B Signal Transducer and Activator 
of Transcription 5B 
89.9 ol 
STAT6 Signal Transducer and Activator 
of Transcription 6 
94.1 ol 
SYK Spleen Associated Tyrosine 
Kinase 
72.1 ol 
TNS1 Tensin 1 185.7 ol 
TNS3 Tensin 3 155.3 ol 
TNS4 Tensin 4 76.8 ol 
TYK2 Tyrosine Kinase 2 133.7 hORF 9.1 
VAV1 Vav Guanine Nucleotide 
Exchange Factor 1 
98.3 ol 
YES1 YES Proto-Oncogene 1, Src 
Family Tyrosine Kinase 
60.8 ol 
ZAP70 Zeta Chain of T Cell Receptor 
Associated Protein Kinase 70 
69.9 ol 
 
 
Table 2S. RFP expression of SH2/PTB prey library after MaMTH assay. The RFP values are 
shown as average of 3 biological replicates after RFP background was subtracted, proteins that 
show lower signal than background are indicated in red.  
Protein RFP 
normalised 
signal 
 Protein RFP 
normalised 
signal 
 Protein RFP 
normalised 
signal 
ABL1 259.3  GRB14 -136.0  SHB 96.0 
ABL2 -63.0  GRB2 211.7  SHC 2497.7 
BCAR3 207.3  GRB7 709.0  SHC3 223.3 
BLK 2249.7  HCK -67.0  SHC4 1526.7 
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BLNK -97.7  HSHD2 -144.7  SHD 3845.7 
BMX 166.7  IRS1 625.3  SHF 486.0 
BTK -10.0  ITK 949.0  SLA 133.0 
CBL 118.3  LCK 1.0  SLA2 3005.7 
CBLB -30.0  LCP2 41.7  SOCS1 365.7 
CBLC 241.0  LYN 26.7  SOCS2 1763.0 
CHN1 145.7  MATK 51.3  SOCS3 139.3 
CHN2 2807.0  NCK1 177.7  SOCS4 214.3 
CISH 106.3  NCK2 3250.3  SOCS5 278.0 
CLNK 167.0  PIK3R1 18.3  SOCS6 546.0 
CRK 84.3  PIK3R2 2799.0  SRC 445.0 
CRK2 198.7  PIK3R3 1091.3  SRMS 179.0 
CRKL 648.0  PTPN11 9.3  STAPI 1620.0 
CSK 344.3  PTPN6 -92.7  STAT1 1042.7 
DAPPI 121.0  RASR1 958.0  STAT2 824.0 
DOK1 1564.3  RIN1  -187.3  STAT3 965.3 
DOK2 589.3  RIN2 -104.7  STAT4 196.0 
DOK3 -59.3  RIN3 117.0  STAT5A 137.3 
DOK4 203.0  SH2B1 180.7  STAT5B 1573.3 
DOK6 234.0  SH2B2 2437.7  STAT6 1501.0 
DOK7 79.3  SH2D1A 2148.0  SYK 1291.3 
FER -98.7  SH2D1B 784.3  TNS1 198.7 
FES 249.3  SH2D2A 367.0  TNS3 1649.3 
FGR 127.7  SH2D3A 35.0  TNS4 407.3 
FRK 332.3  SH2D3C 303.7  TYK2 844.0 
FYN 246.3  SH2D4A 945.3  VAV1 3581.7 
GRAP2 212.7  SH2D4B 3595.7  YES1 378.7 
GRAPL 1282.0  SH2B3 -17.7  ZAP70 2273.0 
GRB10 59.0  SH3BP2 1130.7    
 
 
Table 3S.  List of proteins in SH2/PTB library that are considered as ErbB2 interactors after 
this study and used in screening against ErbB2 ex16del, ErbB2 T798M and ErbB2 K753A. 
Protein Protein Protein Protein 
CRKL SH2D3A SOCS3 CBL 
CSK SH2D4B SRMS CHN2 
GRB2 SCH1 STAT5B CLNK 
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NCK2 SHD ZAP70 DOK1 
SH2D1A SLA CRK2 DOK7 
SH2D1B SLA2 DOK2 FYN 
  
 
Table 4S. List of missing proteins in SH2/PTB library. Known interactors are indicated 
according to BioGRID database (https://thebiogrid.org/).  
Gene Full name Known 
interactor 
 Gene Full name Known 
interactor 
DOK5 Docking Protein 
5 
  PTK6 Protein Tyrosine 
Kinase 6 
+ 
FRS1 Fibroblast 
growth factor 
Receptor  
Substrate 1 
  SH2D5 SH2 Domain 
Containing 5 
+ 
FRS2 Fibroblast 
growth factor 
Receptor 
Substrate 2 
  SH2D6 SH2 Domain  
Containing 6 
 
FRS3 Fibroblast 
growth factor 
Receptor 
Substrate 3 
+  SH2D7 SH2 Domain 
Containing 7 
 
GRAP GRB2-related 
adapter protein 
+  SHC2 SHC Adaptor 
Protein 2 
+ 
INPP5D Inositol 
Polyphosphate-
5-Phosphatase D 
  SHE Src Homology2 
Domain 
Containing 
 E 
 
INPPL1 Inositol 
Polyphosphate 
Phosphatase 
Like 1 
  SOCS7 Suppressor of 
 Cytokine 
Signaling 7 
 
IRS4 Insulin Receptor 
 Substrate 4 
+  SUPT6H SPT6 Homolog, 
 Histone 
Chaperone 
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JAK1 Janus Kinase 1 +  TEC Tec Protein 
Tyrosine Kinase 
+ 
JAK2 Janus Kinase 1 +  TENC1 Tensin 2 + 
JAK3 Janus Kinase 1   TXK TXK Tyrosine 
Kinase 
+ 
PLCG1 Phospholipase C 
Gamma 1 
+  VAV2 Vav Guanine 
Nucleotide 
Exchange Factor 2 
+ 
PLCG2 Phospholipase C 
Gamma 2 
+  VAV3 Vav Guanine  
Nucleotide 
Exchange Factor 3 
+ 
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